Annual CFO
-$48.45 M
+$11.09 M+18.62%
December 31, 2023
Summary
- As of February 7, 2025, ACHL annual cash flow from operations is -$48.45 million, with the most recent change of +$11.09 million (+18.62%) on December 31, 2023.
- During the last 3 years, ACHL annual CFO has fallen by -$23.20 million (-91.86%).
- ACHL annual CFO is now -242.59% below its all-time high of -$14.14 million, reached on December 31, 2019.
Performance
ACHL Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
N/A
September 1, 2024
Summary
- ACHL quarterly cash flow from operations is not available.
Performance
ACHL Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFO
N/A
September 1, 2024
Summary
- ACHL TTM cash flow from operations is not available.
Performance
ACHL TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ACHL Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +18.6% | - | - |
| 3 y3 years | -91.9% | - | - |
| 5 y5 years | -242.6% | - | - |
ACHL Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +18.6% | ||||
| 5 y | 5-year | -242.6% | +18.6% | ||||
| alltime | all time | -242.6% | +18.6% |
Achilles Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2024 | - | -$17.50 M(-1.9%) | -$17.50 M(-69.2%) |
| Dec 2023 | -$48.45 M(-18.6%) | - | - |
| Mar 2023 | - | -$17.85 M(-7.7%) | -$56.75 M(-4.7%) |
| Dec 2022 | -$59.53 M(+0.4%) | -$19.34 M(+514.0%) | -$59.53 M(+9.3%) |
| Sep 2022 | - | -$3.15 M(-80.8%) | -$54.48 M(-9.8%) |
| Jun 2022 | - | -$16.41 M(-20.5%) | -$60.43 M(-3.6%) |
| Mar 2022 | - | -$20.64 M(+44.4%) | -$62.70 M(+5.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$59.28 M(+134.8%) | -$14.29 M(+57.0%) | -$59.28 M(+31.8%) |
| Sep 2021 | - | -$9.10 M(-51.3%) | -$45.00 M(+25.3%) |
| Jun 2021 | - | -$18.68 M(+8.4%) | -$35.90 M(+108.4%) |
| Mar 2021 | - | -$17.22 M(+162.3%) | -$17.22 M(+162.3%) |
| Dec 2020 | -$25.25 M(+78.6%) | - | - |
| Mar 2020 | - | -$6.57 M | -$6.57 M |
| Dec 2019 | -$14.14 M | - | - |
FAQ
- What is Achilles Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Achilles Therapeutics?
- What is Achilles Therapeutics annual CFO year-on-year change?
- What is the all time high quarterly CFO for Achilles Therapeutics?
- What is the all time high TTM CFO for Achilles Therapeutics?
What is Achilles Therapeutics annual cash flow from operations?
The current annual CFO of ACHL is -$48.45 M
What is the all time high annual CFO for Achilles Therapeutics?
Achilles Therapeutics all-time high annual cash flow from operations is -$14.14 M
What is Achilles Therapeutics annual CFO year-on-year change?
Over the past year, ACHL annual cash flow from operations has changed by +$11.09 M (+18.62%)
What is the all time high quarterly CFO for Achilles Therapeutics?
Achilles Therapeutics all-time high quarterly cash flow from operations is -$3.15 M
What is the all time high TTM CFO for Achilles Therapeutics?
Achilles Therapeutics all-time high TTM cash flow from operations is -$6.57 M